Cynapsus Therapeutics

Toronto, Canada Founded: 2004 • Age: 22 yrs Acquired By Sunovion
Treatments for CNS disorders, including Parkinsons OFF episodes, are developed.

About Cynapsus Therapeutics

Cynapsus Therapeutics is a company based in Toronto (Canada) founded in 2004 was acquired by Sunovion in August 2016.. Cynapsus Therapeutics has raised $25.06 million across 6 funding rounds from investors including Orbimed, Sunovion and Aisling Capital. Cynapsus Therapeutics offers products and services including APL-130277.

  • Headquarter Toronto, Canada
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Cynapsus Therapeutics Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $25.06 M (USD)

    in 6 rounds

  • Latest Funding Round
    $16.75 M (USD), Post-IPO

    Apr 10, 2015

  • Investors
    Orbimed

    & 3 more

  • Employee Count
    Employee Count
  • Acquired by
    Sunovion

    (Aug 31, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Cynapsus Therapeutics

Cynapsus Therapeutics offers a comprehensive portfolio of products and services, including APL-130277. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Sublingual thin film for on-demand management of Parkinson's OFF episodes.

Funding Insights of Cynapsus Therapeutics

Cynapsus Therapeutics has successfully raised a total of $25.06M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $16.75 million completed in April 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 6
  • Last Round Post-IPO — $16.8M
  • First Round

    (29 Sep 2011)

  • Investors Count 3
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2015 Amount Post-IPO - Cynapsus Therapeutics Valuation

investors

Jul, 2014 Amount Grant - Cynapsus Therapeutics Valuation

investors

Apr, 2014 Amount Series B - Cynapsus Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Cynapsus Therapeutics

Cynapsus Therapeutics has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Sunovion and Aisling Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
Founded Year Domain Location
PE firm investing in the US
Founded Year Domain Location
Venture capital firm focused on tech sectors
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Cynapsus Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Cynapsus Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Cynapsus Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Cynapsus Therapeutics

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Cynapsus Therapeutics

Frequently Asked Questions about Cynapsus Therapeutics

When was Cynapsus Therapeutics founded?

Cynapsus Therapeutics was founded in 2004 and raised its 1st funding round 7 years after it was founded.

Where is Cynapsus Therapeutics located?

Cynapsus Therapeutics is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.

Is Cynapsus Therapeutics a funded company?

Cynapsus Therapeutics is a funded company, having raised a total of $25.06M across 6 funding rounds to date. The company's 1st funding round was a Series B of $20M, raised on Sep 29, 2011.

What does Cynapsus Therapeutics do?

Cynapsus Therapeutics was founded in 2004 in Toronto, Canada, within the biotechnology sector. Focus is placed on developing a sublingual thin film formulation of apomorphine hydrochloride, known as APL-130277, for managing OFF episodes in advanced Parkinsons disease patients. A Phase 2 clinical trial for this product candidate has been successfully completed. Operations center on CNS disorder treatments, with apomorphine currently approved only as a subcutaneous injection in the United States.

What products or services does Cynapsus Therapeutics offer?

Cynapsus Therapeutics offers APL-130277.

Who are Cynapsus Therapeutics's investors?

Cynapsus Therapeutics has 4 investors. Key investors include Orbimed, Sunovion, Aisling Capital, and Venrock.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available